E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of symptomatic dengue disease |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of dengue disease with clinical symptoms |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6 and 12 months in preventing symptomatic virologically-confirmed dengue cases, regardless of the severity, due to any of the four serotypes |
|
E.2.2 | Secondary objectives of the trial |
Efficacy of CYD dengue vaccine in preventing:
- Symptomatic virologically-confirmed dengue cases 28 days (D28) after the third injection up to the end of the active phase due to at least 3 serotypes and due to each of the 4 serotypes.
- Symptomatic virologically-confirmed dengue cases after at least 1 dose due to any of the 4 serotypes, due to at least 3 serotypes, and due to each of the 4 serotypes.
- Symptomatic virologically-confirmed dengue cases after 2 doses due to any of the 4 serotypes, due to at least 3 serotypes, and due to each of the 4 serotypes.
Safety in all subjects and reactogenicity in a subset
Dengue immune response in a subset
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
An individual must fulfill all of the following criteria in order to be eligible for trial enrolment:
1) Aged 9 to 16 years on the day of inclusion and resident of the site zone
2) Subject in good health, based on medical history and physical examination
3) Assent form or informed consent form has been signed and dated by the subject (based on local regulations), and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (and by an independent witness if required by local regulations)
4) Subject able to attend all scheduled visits and to comply with all trial procedures |
|
E.4 | Principal exclusion criteria |
An individual fulfilling any of the following criteria is to be excluded from trial enrolment:
1) Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination)
2) Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
3) Planned participation in another clinical trial during the present trial period
4) Self-reported or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
5) Self-reported seropositivity for Human Immunodeficiency Virus (HIV) infection
6) Self-reported systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
7) Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
8) Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response
9) Planned receipt of any vaccine in the 4 weeks following any trial vaccination
10) Deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized involuntarily
11) Current alcohol abuse or drug addiction that may interfere with the subject’s ability to comply with trial procedures
12) Identified as a site employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as a family member (i.e., immediate, husband, wife and their children, adopted or natural) of the site employees or the Investigator
Temporary Contraindications
A prospective subject should not be included in the study until the following condition and/or symptoms are resolved:
13) Febrile illness (temperature ≥ 38.0°C) or moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination
14) Receipt of any vaccine in the 4 weeks preceding the first trial vaccination |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Symptomatic virologically-confirmed dengue cases due to any of the 4 serotypes > 28 days after the third injection up to the end of the active phase |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
> 28 days after the third injection up to the end of the active phase (1 year after the third vaccination) |
|
E.5.2 | Secondary end point(s) |
Efficacy:
- Symptomatic virologically-confirmed dengue cases 28 days (D28) after the third injection up to the end of the active phase due to at least 3 serotypes and due to each of the 4 serotypes.
- Symptomatic virologically-confirmed dengue cases after at least 1 dose due to any of the 4 serotypes, due to at least 3 serotypes, and due to each of the 4 serotypes.
- Symptomatic virologically-confirmed dengue cases after 2 doses due to any of the 4 serotypes, due to at least 3 serotypes, and due to each of the 4 serotypes.
Safety: Serious adverse events and adverse events of special interest (AESIs)
Reactogenicity: Non-serious AESIs and adverse events
Dengue immune response: serotype specific neutralizing antibodies
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Efficacy: See endpoint
Safety throughout the study.
Reactogenicity: Non-serious AESIs up to 7 days after each injection and adverse events up to D28 after each injection
Dengue immune response prior to first injection, after the second and third injections, and each year during 5 years after the third injection
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Brazil |
Colombia |
Honduras |
Mexico |
Puerto Rico |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 6 |